Ruibing Wang received his B.S. degree in chemistry from Jilin University (Changchun, China) in 2002 and a Ph.D. degree in organic chemistry from Queen's University (Kingston, Canada) in 2007. Due to the excellence of his Ph.D. research, his thesis was entitled the “Outstanding Thesis Award” by Queen’s School of Graduate Studies. He stayed in the same laboratory as a Postdoctoral Fellow at Queen's University (2007-2008) and then moved to the Steacie Institute for Molecular Sciences at the National Research Council of Canada as a Research Associate for about two years. Since late 2009, he has been working as a Senior R&D Scientist in the field of nuclear medicine, medical devices, and radiopharmaceutical development at Nordion Inc., a world-leading radiopharmaceutical firm based in Ottawa, Canada. He worked as the Technical Design Authority Chemist for GSK Bexxar product (a radiolabeled antibody for non-Hodgkin’s lymphoma diagnostics and therapy). His research activities encompass primarily three areas: the development of innovative and efficient analytical methods for the quality control of radiopharmaceuticals and radiochemical APIs (active pharmaceutical ingredients) and this involves HPLC, UPLC, ITLC, immunoreactivity assay, alpha spectrometry, gamma spectrometry, and so forth; the research and development of novel radiopharmaceuticals, nuclear medicine, and medical devices (such as microparticles and nanomedicine) for cancer diagnostics and therapeutics and these include supramolecular formulation and nanoformulation of active drug components for targeted delivery and controlled drug release; radiopharmaceuticals and radiochemical API manufacturing process and quality control methods improvements.
Biography Updated on 6 February 2012